AOP ACTIVITIES AT THE OECD

Workshop AOPs: From Research to Regulation
3 - 5 September 2014

Joop de Knecht
Principal Administrator
OECD Test Guidelines Programme
Environmental, Health and Safety Division
Launch of the Programme at OECD

• The AOP Development Programme was launched at OECD in 2012, under the umbrella of the Advisory Group on Molecular Screening and Toxicogenomics (Programme on Chemical Safety).

• AOPs are a central concept in future work at OECD on predictive toxicology, improving uses and applications of mechanistic information for both future testing and assessment needs.

• Several OECD groups are involved, interdisciplinary nature of the work
AOP Development Programme: an horizontal activity at OECD

The OECD programme on the development of AOPs addresses the needs of:

- the OECD Test Guidelines Programme for the identification of new in vitro test methods that are candidates to become OECD Test Guidelines;
- The OECD QSAR Project for the identification of new methods/profilers for grouping chemicals;
- the OECD Hazard Assessment activities for the development of IATAs for defined hazard endpoints.
Framework for the development and use of IATAs

- Approaches to decide on the adverse effect of a chemical by using existing information, alternative methods and tailored testing strategies.
- Starts with the formulation of plausible and testable hypotheses about the toxicological potential of a chemical based on existing information and/or information derived from lower tier testing.
- The information would then be used to evaluate data gaps and what testing approaches if any would be most appropriate to undertake in order to elucidate the toxicological profile of that substance.
• The vision is that the results from appropriate combinations of selected \textit{in silico}, \textit{in chemico}, and \textit{in vitro} tests that target key events along well defined AOPs could provide sufficient information for hazard and risk assessments with minimal, but well-tailored need for further testing.

• The knowledge of an adverse outcome pathway or mode of action can provide the scientific framework for developing and using IATAs.
AOPs/MoAs could be used to:
• develop (Q)SARs
• support grouping of chemicals into chemical categories for subsequent data gap filling for a specific endpoint using read-across or trend analysis
• develop testing strategies
• select methods for TG development
• interpret results from non-standard test methods
Use of the AOP concept to categorise chemicals for a specific endpoint
Use of an AOP to develop QSARs
Use of an AOP/MoA in a testing strategy

Tier 1
- Positive
- Negative
  - Equivocal

Tier 2
- In vitro assay 1
  - Positive
  - Negative
    - Equivocal
- In vitro assay 2
  - Positive
  - Negative

Tier 3
- Positive
- Negative
  - Equivocal

MIE
KE 1
KE 2
AO
Aim

- To test the applicability of the AOP/MoA concept as a framework for developing and using IATAs and to refine the framework as far as possible.
- Build consensus that the AOP/MoA concept is a good basis for developing and using IATAs,
- Determine for which type of IATA, the AOP/MoA concept can be used,
- Discuss and refine different stages of development of an AOP
- Decide which of the different stages is most suitable for each type of IATA and their associated purpose.
Relevant documentation published at OECD

• **Template format** for project proposals

• **Guidance document on developing and assessing AOP** (2013), No. 184 Series Testing and Assessment

• **User handbook** (more practical and wiki-oriented than the guidance, *under preparation*)
Functioning of the AOP Development Programme at OECD

• The OECD Advisory Group on Molecular Screening and Toxicogenomics (EAGMST) is a large group of experts from various areas of toxicology.

• Experts are designated by governmental or non-governmental affiliations (academia, agencies, industry, animal welfare groups, scientific societies, etc.)

• The EAGMST meets once a year before summer and holds a teleconference, usually in December to keep pace with new developments.
Functioning of the AOP Development Programme at OECD

- **Project proposals** to develop new AOPs can be made by members of EAGMST or the public (academia, scientific societies, industry groups, etc.)

- **Project proposals** can be submitted any time of the year to the Secretariat who makes them available to the EAGMST for their review.

- The AOP Development Programme maintains a **rolling work plan**, updated twice a year with new project proposals and new information on existing projects.
  - Twice a year, project proposals are reviewed and included in the work plan if justified and in line with the objectives of the Programme.
Where can I find relevant information?

- A public web-page provides summary information to the public on the AOP development programme, including **titles of AOP** on the workplan and **lead** organisations/countries, relevant **templates** for making proposals, **guidance** on how to develop AOPs, etc.

Where can AOPs under development be found?

- A *wiki-based* interface has been developed to enable AOP description (MIE, KE, KER, AO)
  - [http://aopwiki.org](http://aopwiki.org)
    - → *see Stephen Edwards presentation*

- The AOP wiki will be *publicly launched* by end of September 2014

- All AOPs should be considered at this stage as drafts under development
PROPOSED PROCESS FOR THE DEVELOPMENT OF AOPs
(This is work in progress and might be revised based on experience gained)
Status of AOPs developed at OECD

- AOPs are **scientific descriptive documents** depicting interactions, events, outcome, etc.: as such, they have **no regulatory implication**

- AOP can be developed in parallel of scientific publications (OECD work **does not preclude scientists to publish** in the literature)

- AOPs can be seen as continuously developing, and **OECD-agreed versions of AOPs can evolve** as science progresses
Conclusions and take home messages

• AOP Development Programme is evolving fast with participation of multiple groups of experts in various areas of toxicology

• The public can make project proposals to develop AOPs (published guidance for users)

• AOPwiki soon publicly available (end Sept. 2014) to enable crowd-sourcing
Organizing the adverse outcome pathways knowledge – the Effectopedia way.

Hristo Aladjov, 27 August, Prague
Visually Express Biological Context

- **Cause A**
- **Effect B**
- **Effect C**

Short term

Mid term

Cellular

Tissue
Effectopedia’s Pathway Space

- Life stage
- Taxonomy
- Gender
- Generation
- Time to effect
- Level of biological organization
- ...

- User expandable set of biological context dimensions
- Interface allows easy switching between pathway space 2D projections
Pathway elements

Chemical Substance

Lin k

MIE

f(x)

In-Silico Test Method
- Applicability domain
- Executable source code
- Training Set
- Verification Set

In-Chemico Test Method
- Guideline Ref.
- Formal (ISAtab) assay description
- Applicability domain
- Set of tested chemical compounds

In-Vitro Test Method
- Guideline Ref.
- Formal (ISAtab) assay description
- Applicability domain
- Set of tested chemical compounds

In-Vivo Test Method
- Guideline Ref.
- Formal (ISAtab) assay description
- Applicability domain
- Set of tested chemical compounds
Pathway elements – test response mapping

Test response mapping (function)

Concentration, [Log M]

In vivo effect

Measured effect

Concentration, [Log M]
Pathway elements

- **Chemical Substance**
  - Mid-term Adverse Outcome
  - Long-term Biological Effect

- **In-Vitro**
  - Comp 1 Obs. 1
  - Comp 2 Obs. 1
  - Comp N Obs. 1

- **In-Vivo**
  - Comp 1 Obs. 1
  - Comp 2 Obs. 1
  - Comp M Obs. 1

- **Biological Effect**
  - Hypothetical Direct Threshold Response

- **MIE**

- **Link**
  - Hypothetical Dose-response

- **Organ**

- **System**

- **Individual**

- **Cellular**

- **Organelle**

- **Molecular**